Parnax Lab Ltd (PARNAXLAB) Share Price & Fundamentals

What we do

Parnax Lab Limited manufactures and exports pharmaceutical formulations, cosmetics, herbal/ayurvedic, and nutraceutical products with a focus on domestic and international markets.

Founded in

1,982

Market share

Significant presence in emerging pharmaceutical markets such as Nigeria, Kazakhstan, Kenya, and Mauritius; expanding into South East Asia and Latin America.

Problem solved

Provides high-quality pharmaceutical and herbal products targeting healthcare needs in domestic and emerging international markets.

Top clients or who we serve

B2B pharmaceutical companies, multinational clients in India and abroad, and emerging markets in Africa, CIS, and Latin America.

Key management

Mihir P. Shah - Managing Director and CEO; Binoy B. Shah - Executive Director and CFO; Mr. Baiju Shah - Director and CFO.

Our journey and innovations

Incorporated in 1982, transitioned from financing to pharma manufacturing; achieved ISO 9002 accreditation; expanded manufacturing with WHO-approved facilities.

Where we operate

India with export markets including Nigeria, Kazakhstan, Kenya, Mauritius, South East Asia, CIS, and Latin America.

Top products or what we offer

Pharmaceutical formulations, cosmetics, herbal/ayurvedic formulations, and FSSAI-approved nutraceutical products.

Top brands

-

Raw materials needed

Pharmaceutical active ingredients, herbal extracts, packaging materials.

Raw materials supplier

Not specified; sourced from approved suppliers meeting quality standards.

Recurring vs cyclical contribution

Revenue primarily from recurring manufacturing contracts and export sales.

Our industry position

Well-placed manufacturer with WHO-approved facilities, strong export focus, and growing presence in emerging markets.

Financial highlights

FY2024-25 revenue approx. Rs. 7.02 crore; net profit Rs. 1.39 crore; steady though slightly declined revenue versus previous year.

Geographical revenue split

-

Order book

-

Whats driving growth

Expansion into emerging markets, diversified product portfolio, and state-of-the-art manufacturing enhancing export capabilities.

Our future plans

Focus on increasing sales volumes, expanding geographical reach, and leveraging accredited manufacturing units for growth.

Our green promise

-

Our people and values

Emphasizes ethical standards, employee relations, and promotes talent retention and development.

Key challenges ahead

Market concentration risks and dependency on limited markets; seeking diversification to mitigate these risks.

Interesting facts

Operational since 1982 with ISO 9002 accreditation and WHO-approved manufacturing; subsidiary Naxpar Pharma has advanced facilities.

Risks and strategy

Dependent on emerging markets; mitigation via expansion and broadening customer base.